Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

被引:7
作者
Hatooka, Masahiro [1 ]
Kawaoka, Tomokazu [1 ]
Aikata, Hiroshi [1 ]
Morio, Kei [1 ]
Kobayashi, Tomoki [1 ]
Hiramatsu, Akira [1 ]
Imamura, Michio [1 ]
Kawakami, Yoshiiku [1 ]
Murakami, Eisuke [2 ]
Waki, Koji [2 ]
Honda, Yoji [3 ]
Mori, Nami [3 ]
Takaki, Shintaro [3 ]
Tsuji, Keiji [3 ]
Kohno, Hirotaka [4 ]
Kohno, Hiroshi [4 ]
Moriya, Takashi [5 ]
Nonaka, Michihiro [6 ]
Hyogo, Hideyuki [6 ]
Aisaka, Yasuyuki [6 ]
Chayama, Kazuaki [1 ]
机构
[1] Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Med & Mol Sci, Hiroshima, Japan
[2] Hiroshima City Asa Hosp, Hiroshima, Japan
[3] Hiroshima Red Cross Hosp, Hiroshima, Japan
[4] Kure Med Ctr, Hiroshima, Japan
[5] Chugoku Rousai Hosp, Hiroshima, Japan
[6] Hiroshima Gen Hosp, Hiroshima, Japan
关键词
HCC; sorafenib; hepatic arterial infusion chemotherapy; transcatheter arterial chemoembolization; 5-FLUOROURACIL/INTERFERON COMBINATION THERAPY; VEIN TUMOR THROMBOSIS; INTRAARTERIAL; 5-FLUOROURACIL; INTERFERON-ALPHA; EFFICACY; CRITERIA; VERSION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE). Patients and Methods: In this retrospective cohort study, 123 patients with HCC refractory to TACE, with Child-Pugh A and free of extrahepatic metastasis, were divided into two groups: 65 received HAIC and 58 received sorafenib. Since the size of main tumor and portal vein invasion were significantly different between the HAIC and sorafenib groups, we selected 48 patients from the 65 patients of the HAIC group and 48 from the 58 patients of the sorafenib group. The model used one-to-one matching between the two groups using the case-control method matching method. The clinical characteristics of patients of the case-control HAIC (n=48) and sorafenib groups (n=48) were similar. Overall survival, time to progression and time to treatment failure (TTTF) were compared between the two groups. Results: The median survival time and TTTF were significantly longer in the sorafenib group than in the HAIC group (15 and 12.2 months versus 8 and 4.4 months, respectively; p=0.021 and p=0.002, respectively). Multivariate analysis identified male gender (p=0.008), relative tumor size < 50% (p=0.012), alpha-fetoprotein < 400 ng/ml (p=0.005), and treatment with sorafenib (p=0.001) as significant and independent determinants of better overall survival. Conclusion: In patients with HCC refractory to TACE, overall survival was favorable in those treated with sorafenib rather than HAIC.
引用
收藏
页码:3523 / 3529
页数:7
相关论文
共 18 条
[1]   Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis - Analysis of 48 cases [J].
Ando, E ;
Tanaka, M ;
Yamashita, F ;
Kuromatsu, R ;
Yutani, S ;
Fukumori, K ;
Sumie, S ;
Yano, Y ;
Okuda, K ;
Sata, M .
CANCER, 2002, 95 (03) :588-595
[2]   Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [J].
Arnold, Benjamin ;
Mitchell, Sandra A. ;
Lent, Lauren ;
Mendoza, Tito R. ;
Rogak, Lauren J. ;
Barragan, Natalie M. ;
Willis, Gordon ;
Medina, Mauricio ;
Lechner, Suzanne ;
Penedo, Frank J. ;
Harness, Jay K. ;
Basch, Ethan M. .
SUPPORTIVE CARE IN CANCER, 2016, 24 (07) :2843-2851
[3]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[4]   THE DESIGN AND INTERPRETATION OF CASE-CONTROL STUDIES OF PERINATAL-MORTALITY [J].
CLARKE, M ;
CLAYTON, D .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1981, 113 (06) :636-645
[5]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[6]   Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization [J].
Ikeda, Masafumi ;
Mitsunaga, Shuichi ;
Shimizu, Satoshi ;
Ohno, Izumi ;
Takahashi, Hideaki ;
Okuyama, Hiroyuki ;
Kuwahara, Akiko ;
Kondo, Shunsuke ;
Morizane, Chigusa ;
Ueno, Hideki ;
Satake, Mitsuo ;
Arai, Yasuaki ;
Okusaka, Takuji .
JOURNAL OF GASTROENTEROLOGY, 2014, 49 (05) :932-940
[7]   Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases [J].
Katamura, Yoshio ;
Aikata, Hiroshi ;
Kimura, Yuki ;
Kawaoka, Tomokazu ;
Takaki, Shintaro ;
Waki, Koji ;
Hiramatsu, Akira ;
Kawakami, Yoshiiku ;
Takahashi, Shoichi ;
Ishikawa, Masaki ;
Hieda, Masashi ;
Kakizawa, Hideaki ;
Chayama, Kazuaki .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (06) :1117-1122
[8]   Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis [J].
Katamura, Yoshio ;
Aikata, Hiroshi ;
Takaki, Shintaro ;
Azakami, Takahiro ;
Kawaoka, Tomokazu ;
Waki, Koji ;
Hiramatsu, Akira ;
Kawakami, Yoshiiku ;
Takahashi, Shoichi ;
Kenjo, Masahiro ;
Toyota, Naoyuki ;
Ito, Katsuhide ;
Chayama, Kazuaki .
JOURNAL OF GASTROENTEROLOGY, 2009, 44 (05) :492-502
[9]   Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? [J].
Kirikoshi, Hiroyuki ;
Yoneda, Masato ;
Mawatari, Hironori ;
Fujita, Koji ;
Imajo, Kento ;
Kato, Shingo ;
Suzuki, Kaori ;
Kobayashi, Noritoshi ;
Kubota, Kensuke ;
Maeda, Shin ;
Nakajima, Atsushi ;
Saito, Satoru .
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (16) :1933-1939
[10]   Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JS']JSH-HCC Guidelines) [J].
Kokudo, Norihiro ;
Hasegawa, Kiyoshi ;
Akahane, Masaaki ;
Igaki, Hiroshi ;
Izumi, Namiki ;
Ichida, Takafumi ;
Uemoto, Shinji ;
Kaneko, Shuichi ;
Kawasaki, Seiji ;
Ku, Yonson ;
Kudo, Masatoshi ;
Kubo, Shoji ;
Takayama, Tadatoshi ;
Tateishi, Ryosuke ;
Fukuda, Takashi ;
Matsui, Osamu ;
Matsuyama, Yutaka ;
Murakami, Takamichi ;
Arii, Shigeki ;
Okazaki, Masatoshi ;
Makuuchi, Masatoshi .
HEPATOLOGY RESEARCH, 2015, 45 (02) :123-127